Conditions for the achievement of pharmaceutical innovation for sustainable development: lessons from India
by Dinesh Abrol
World Review of Science, Technology and Sustainable Development (WRSTSD), Vol. 3, No. 4, 2006

Abstract: This paper shows the post-TRIPS experience to be contradicting the overstated claim that ''the adverse effect of TRIPS Agreement on prices of patented medicines would be adequately compensated by the benefits of technology transfer and domestic R&D''. It argues that policymakers cannot continue to formulate their strategic interventions with an understanding that ''strong IPRs are going to help define the pharmaceutical knowledge markets to be competitive and favourable for the development of people oriented innovations''. Strategic interventions of the government should make the pharmaceutical sector to work for the benefit of therapies needed by the people of India and LDCs.

Online publication date: Mon, 16-Oct-2006

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the World Review of Science, Technology and Sustainable Development (WRSTSD):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com